Sign in Subscribe
Pharmaceutical industry

Melphalan, Prednisone, and Thalidomide Combination Therapy Show Promising Results in Newly Diagnosed Multiple Myeloma Patients

Strategic Insights

— 1 min read

A Phase II study evaluating the clinical results of a combination therapy of melphalan, prednisone, and thalidomide (MPT) in newly diagnosed multiple myeloma patients presented promising data at the American Society of Hematology 46TH Annual Meeting in 2004. The study, led by Antonio Palumbo, MD from the Italian Multiple Myeloma Study Group, reported a statistically significant difference in event-free survival between the MPT arm and the MP arm, with a median event-free survival of 25.2 months versus 13.7 months, respectively.

Key Takeaways:

  • The MPT combination therapy resulted in a statistically significant difference in event-free survival, with a median of 25.2 months compared to 13.7 months for the MP arm.
  • The overall response rate among patients in the MPT arm was 77.1%, with 27.7% complete response and near complete response (CR+nCR), 77.1% partial remission (PR), 14.5% stable disease (SD), and 8.4% progressive disease (PD).
  • The major acute adverse events were neurological toxicity (32%), grade III-IV infections (10%), and deep-vein thrombosis (19%), but the incidence of these events decreased with the introduction of low-molecular weight heparin (enoxaparin).
  • Thalidomide discontinuation was required in 42% of patients due to thromboembolic events, infections, constipation, and hematologic toxicity, and dose-reduction in 27% of patients primarily due to neurotoxicities and constipation.
  • The MPT regimen was well-tolerated, with only 5 patients experiencing severe acute adverse events, including septicemia, pulmonary thrombo-embolism, and heart failure.

Statistics:

  • 177 patients were evaluated on an intent-to-treat basis.
  • The median age of patients in the study was 72, with a range of 60-85.
  • The MPT regimen included 6 monthly courses of oral melphalan 4 mg/sqm and prednisone 40 mg/sqm for 7 days every month, plus thalidomide 100 mg/day continuously until any sign of progressive disease or relapse.
  • The major adverse events were neurological toxicity (32%), grade III-IV infections (10%), and deep-vein thrombosis (19%), with 2 of 30 patients developing DVTs after enoxaparin introduction.

Sources:

  • American Society of Hematology 46TH Annual Meeting
  • Italian Multiple Myeloma Study Group
  • Celgene Corporation
  • U.S. Food and Drug Administration (FDA)
  • GlaxoSmithKline
  • Warren, New Jersey

Read more